东江集团控股(02283) - 2024 - 中期财报

Financial Performance - Revenue for the six months ended June 30, 2024, was HK$1,007,209,000, representing a 17.6$855,914,000 in the same period of 2023[15]. - Profit for the period increased to HK$79,742,000, up 45.7$54,699,000 in the prior year[15]. - Basic earnings per share rose to 9.6 HK cents, compared to 6.6 HK cents in the previous year, reflecting a 45.5% increase[15]. - Proposed interim dividend per share increased to 4.0 HK cents, up from 2.8 HK cents, marking a 42.9% rise[15]. - Gross profit margin improved to 24.8%, up from 23.3% in the previous year[15]. - Net profit margin increased to 7.9%, compared to 6.4% in the same period last year[15]. - Return on equity rose to 5.1%, up from 3.6% in the previous year[15]. - Return on assets improved to 3.2%, compared to 2.2% in the prior year[15]. - Gross profit for the first half of 2024 was approximately HK$250.0 million, representing an increase of approximately HK$50.3 million or 25.2% compared to HK$199.7 million in the same period of 2023[42]. - Operating profit increased to HK$102,045,000, a 50.4% rise compared to HK$67,977,000 in the previous year[124]. Revenue Breakdown - Revenue from the mold fabrication business was approximately HK$268.9 million, a 2.1% increase from HK$263.2 million in the same period last year, accounting for 26.7$326.2 million, a 51.2% increase from HK$215.7 million in the first half of 2023[21]. - The commercial telecommunications equipment segment saw revenue rise by 44.2$90.0 million from HK$62.4 million in the previous year[21]. - The plastic components manufacturing business segment generated revenue of approximately HK$738.3 million, a 24.6% increase from HK$592.7 million in the first half of 2023, accounting for approximately 73.3$6.2 million or 22.0% to HK$34.3 million, representing 3.4$10.1 million or 8.1% to HK$135.5 million, accounting for 13.5$927,029,000 in 2024, up from HK$809,721,000 in 2023, a 14.5$332,941,000 in 2024 from HK$277,017,000 in 2023, a rise of 20$381,488,000 in 2024, compared to HK$287,212,000 in 2023, an increase of 32.8$1,060.5 million, a 13.3% increase from HK$935.7 million as of June 30, 2023[25]. - Cash and cash equivalents decreased to HK$1,060,484,000 from HK$1,158,156,000, a decline of 8.4$145,324, a decrease of 16.7% compared to HK$174,316 in the same period of 2023[133]. - The company reported a net decrease in cash and cash equivalents of HK$92,474 for the period, compared to a decrease of HK$4,347 in the previous year[133]. - Current assets included a total of HK$457,268,000 in inventories, up from HK$360,082,000, marking a 27$833,260,000 with a share premium of HK$251,293,000[188]. - The number of awarded shares as of June 30, 2024, decreased to 5,263,630 from 6,312,009 as of January 1, 2024[195]. - The Group's total consideration for shares held under the employee share scheme was HK$13,103,000 as of June 30, 2024, down from HK$17,679,000[190]. Market Outlook - The global GDP growth rate for 2024 is expected to be revised upwards to 2.6%, indicating a steady state of growth in the global economy[82]. - The consumer electronics industry is anticipated to see a significant rebound in the second half of the year, with brand owners preparing for new product launches[82]. - The Group remains optimistic about the long-term development of the medical and health care industry and will continue to explore well-known medical brand customers in both domestic and overseas markets[38][40]. - The Group's implementation of Industry 4.0 has significantly enhanced production efficiency and market competitiveness, contributing to the overall growth in revenue and profit margins[43]. Corporate Governance - The company complied with all code provisions of the Corporate Governance Code during the six months ended June 30, 2024[100]. - The company is committed to strengthening corporate governance measures to ensure transparency and accountability[100]. - The interim financial information has been approved for issue by the Board of Directors on August 26, 2024[134].